The FDA announced last week that it was preparing to resume nationwide surveillance inspections after a brief postponement.
In December, the agency confirmed temporary changes to inspection activities due to COVID-19, as the omicron variant of the virus caused outbreaks across the world. The FDA implemented the changes in the United States on December 29, 2021 to keep its employees and the businesses it regulates safe, outlining plans to continue critical work while postponing some inspection activities.
According to a press release, the FDA determined Feb. 2 that it would resume nationwide surveillance inspections on all products following a decline in COVID-19 cases. The recovery took effect today, February 7.
The FDA said that in addition to resuming surveillance inspections, it continues to conduct both foreign and domestic critical inspections and to monitor food, drugs, medical products and tobacco in several ways, including remote assessments.
Additionally, the FDA plans to move forward with previously scheduled overseas surveillance inspections that have received country clearance and are consistent with CDC Level 1 or 2 COVID-19 travel recommendations. . Planning for new overseas inspections is underway, as the FDA aims to conduct priority overseas inspections beginning in April.
“Throughout all of these activities, the agency remains committed to the health and safety of its investigators and will provide the protection necessary to safely inspect facilities and conduct investigations at ports and in the laboratories of the agency,” the FDA said. noted.